Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial
Christina A. Meyers(The University of Texas MD Anderson Cancer Center), Markus F. Renschler(Princess Margaret Cancer Centre), Walter J. Curran(Piedmont Atlanta Hospital), Minesh P. Mehta(Columbia University), Andrea Bezjak(Princess Margaret Cancer Centre), Jennifer A. Smith(University of California, San Francisco), Ross Siemers(Princess Margaret Cancer Centre), Tim Illidge(University of Manchester), Richard Miller(Princess Margaret Cancer Centre), Ian Kunkler(Princess Margaret Cancer Centre), S. Phan(Princess Margaret Cancer Centre), Laurie E. Gaspar(University of Colorado Cancer Center), Peter D. Eisenberg(Princess Margaret Cancer Centre), James Liebmann(Princess Margaret Cancer Centre), J.H. Meerwaldt(Princess Margaret Cancer Centre), J. Caudrelier(Princess Margaret Cancer Centre), C. Carrié(Princess Margaret Cancer Centre)
Cited by 587
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k